ProQR Therapeutics (PRQR) Non-Current Debt (2016 - 2023)

ProQR Therapeutics has reported Non-Current Debt for 8 years, with the latest figure at $4.6 million in Q4 2023.

• Quarterly Non-Current Debt rose 5.98% year-over-year to $4.6 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $4.6 million (up 5.98% YoY) and the FY2023 annual result came in at $4.6 million, up 5.98% from the prior year.
• Non-Current Debt grew to $4.6 million in Q4 2023 per PRQR's latest filing, from $3.1 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $45.0 million in Q4 2021 and troughed at $3.1 million in Q3 2023.
• A 5-year average of $16.1 million and a median of $12.9 million in 2019 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2021 and 2023: Non-Current Debt jumped 278.77% in 2021, then plunged 90.34% in 2023.
• Over 5 years, Non-Current Debt stood at $14.1 million in 2019, then soared by 37.21% to $19.3 million in 2020, then surged by 133.03% to $45.0 million in 2021, then slumped by 90.31% to $4.4 million in 2022, then gained by 5.98% to $4.6 million in 2023.
• According to Business Quant data, Non-Current Debt over the past three periods registered $4.6 million, $3.1 million, and $3.9 million for Q4 2023, Q3 2023, and Q2 2023 respectively.